Unlock instant, AI-driven research and patent intelligence for your innovation.

5-carboxamido substitued thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family

A technology of metabolites and alkyl groups, which is applied in the field of preparing this pharmaceutical composition and preparing the compound, and can solve problems such as non-drugs

Inactive Publication Date: 2008-01-02
DEVGEN PTE LTD
View PDF14 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] A major disadvantage of some known compounds concerns that the drugs do not work in a selective manner, i.e. they do not choose between different ion channels

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 5-carboxamido substitued thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
  • 5-carboxamido substitued thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
  • 5-carboxamido substitued thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0237] Example 1: Preparation of compounds according to the invention

[0238] The practice of the present invention will employ, unless otherwise indicated, conventional techniques in the fields of synthetic organic chemistry, biological testing and the like, which are within the skill of the art. Such techniques are explained fully in the literature. Unless otherwise indicated, the purity of the compounds was confirmed by liquid chromatography / mass spectrometry (LC / MS) according to Method A or Method B as follows:

[0239] Method A (5 minute gradient):

[0240] HPLC: Waters Alliance 2690 with Photo=- / Diode Array Detector Waters 996. Mass spectrometer: Micromass Platform ZMD LC. Ionization: Electrospray (polarity: negative and positive).

[0241] method:

[0242] Phase: Tosohaas TSK-gel super ODS ( 2 μ m), column: 4.6 * 50mm; Solvent A: water and formic acid (26.5mM); Solvent B: acetonitrile and formic acid (17mM); Flow rate: 2.75ml / min; Gradient 5 minutes: from 100% A...

Embodiment 2

[0474] Example 2: Biological Assay Using C. elegans Screening

[0475] A C. elegans-based high-throughput screen for Kv4.3 modulators has been used to establish the in vivo SAR (structure-activity relationship: effect of chemical structure on biological activity) of compounds according to the invention for Kv4.3.

[0476] The test employed a stable transgenic C. elegans strain that functionally expresses human Kv4.3 in the pharynx and a visual selection GFP marker in the body wall muscle.

[0477] Methods describing the construction of transgenic C. elegans strains expressing human Kv4.3 are described in WO03 / 097682. Briefly, 5 ng / μl pGV8 plasmid (human Kv4.3), 20 ng / μl pDW2821 (GFP-tagged), and 40 ng / μl genomic C. elegans DNA were microinjected into the gonads of wild-type strain N2 to generate practical The strain UG1755. Transgenic animals were isolated and extrachromosomal arrays were integrated into the C. elegans genome. 50% of the cell lines delivering functionally e...

Embodiment 3

[0490] Example 3: Patch clamp analysis

[0491] Cell culture:

[0492] For this assay, a recombinant CHO-K1 cell line stably expressing the human Kv4.3 / KChIP2.2 potassium channel was used. The cells used in this experiment were grown under standard conditions (37°C, supplemented with 7% CO 2air) maintained in continuous culture. CHO-K1 Kv4.3 / KChIP2.2 cells were maintained in Iscove's modified DMEM (Dulbecco's modified Eagle's medium) medium (IMEM), in which the medium was supplemented with 100 U / ml penicillin, 100 μg / ml streptomycin, 7% Fetal calf serum (FCS), 2.5 μg / ml amphotericin, 400 μg / ml G418 and 400 μg / ml Zeocin TM . Cells were passaged every 3-4 days after detachment with trypsin solution. Ensure the quality of cultured cells with viability and contamination testing. Cell culture was performed as described in Protocol D hereinafter.

[0493] Protocol D: Cells in 5% CO 2 and cultured in 94mm Petri dishes at 37°C. Subcultures were performed every 3-4 days by r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
shear viscosityaaaaaaaaaa
electrical resistanceaaaaaaaaaa
Login to View More

Abstract

The present invention relates to compounds that interact with ion channels. In particular, the invention relates to compounds having the structural Formula having the structural Formula (I), (II), (III) or (IV), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or a pharmaceutically acceptable salt and / or solvate thereof, wherein X, Y<1>, Y<2>, R<1>, n, R<3>, R<8>, R<9>, R<10>, L<1>, L<2>, Ar<1> and Ar<2> are defined in claim 1. The invention also relates to methods for preparing said compounds, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in methods for treatment of the human and animal body.

Description

technical field [0001] The present invention relates to compounds that interact with ion channels. [0002] In particular, the present invention relates to compounds that interact with ion channels of the Kv family, especially the Kv4 subfamily. [0003] The invention also relates to processes for the preparation of said compounds, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in methods of treatment of the human and animal body and / or to the use of said compounds in the preparation of such pharmaceutical compositions use in . [0004] The compounds of the present invention are, for example, useful for the prevention and / or treatment of conditions or diseases associated with ion channels, especially for the prevention and / or treatment of conditions or diseases associated with Kv family ion channels, and more particularly for the prevention and / or treatment of Conditions or diseases associated with Kv4 family ion channels. [0005...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/426C07D263/48A61P9/00C07D233/54C07D277/56C07D233/90
CPCC07D417/06C07D417/14C07D277/56C07D271/07C07D239/42C07D263/48C07D333/38C07D417/12C07D233/90A61P1/02A61P1/04A61P1/10A61P1/12A61P1/16A61P1/18A61P3/10A61P5/14A61P7/00A61P7/02A61P7/06A61P9/00A61P9/04A61P9/06A61P9/10A61P9/12A61P11/00A61P11/02A61P11/06A61P13/12A61P15/12A61P17/00A61P17/02A61P17/04A61P17/10A61P17/14A61P17/16A61P19/10A61P21/00A61P21/04A61P25/00A61P25/06A61P25/08A61P25/16A61P25/20A61P25/22A61P25/28A61P27/02A61P27/12A61P27/14A61P29/00A61P31/04A61P31/12A61P31/14A61P31/18A61P35/00A61P35/04A61P39/00A61P39/02A61P43/00C07D233/54
Inventor 彼得拉·布洛姆扬·奥克塔夫·德·克佩尔埃里克·皮埃尔·保罗·勒内·富曼特罗蒂图斯·扬·卡莱塔迪尔克·莱森
Owner DEVGEN PTE LTD